Aclaris Therapeutics, Inc.

Historical 13F Holders

Symbol
ACRS
CUSIP
00461U105
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 00461U105 since 12/18/2024, newest first.

Filer % of Class Filed
Frazier Life Sciences Public Fund, L.P. 13G
5.4% 9/21/2026
Event 9/14/2026
RA Capital Management, L.P. 13G/A Amendment 1
9.1% 8/14/2026
Event 6/30/2026
Vivo Opportunity Fund Holdings, L.P. 13G/A Amendment 1
4.3% 5/12/2026
Event 3/31/2026
BML Investment Partners, L.P. 13G/A Amendment 5 9.9% 4/27/2026
Event 4/23/2026
RA Capital Management, L.P. 13G
6.3% 4/7/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 1 0% 3/26/2026
Event 3/13/2026
Deep Track Capital, LP 13G
7.0% 3/17/2026
Event 3/9/2026
BML Investment Partners, L.P. 13G/A Amendment 4 11.9% 2/9/2026
Event 12/31/2025
BlackRock, Inc. 13G/A Amendment 1 6.2% 1/21/2026
Event 12/31/2025
Bonita Biotech (HK) Ltd 13G/A Amendment 1
9.4% 1/9/2026
Event 12/9/2025
Adage Capital Management, L.P. 13G/A Amendment 2
4.9% 11/13/2025
Event 9/30/2025
Vanguard Group Inc 13G 6.2% 7/29/2025
Event 6/30/2025
Millennium Management LLC 13G/A Amendment 1
3.5% 7/24/2025
Event 6/30/2025
BlackRock, Inc. 13G 5.1% 7/17/2025
Event 6/30/2025
Rock Springs Capital Management LP 13G/A Amendment 1
4.7% 5/15/2025
Event 3/31/2025
Adage Capital Management, L.P. 13G/A Amendment 1
7.6% 5/12/2025
Event 3/31/2025
Millennium Management LLC 13G
5.1% 5/5/2025
Event 4/28/2025
Vanguard Group Inc 13G/A Amendment 1 4.6% 4/30/2025
Event 3/31/2025
BML Investment Partners, L.P. 13G/A Amendment 3 13.3% 2/13/2025
Event 12/31/2024
Adage Capital Management, L.P. 13G
9.0% 2/12/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 15 214 k $1.13 M
2026 Q2 159 121 M $642 M
2026 Q1 143 111 M $414 M
2025 Q4 125 83.7 M $252 M
2025 Q3 105 86.4 M $164 M
2025 Q2 98 94.7 M $134 M
2025 Q1 113 92.7 M $144 M
2024 Q4 106 87.5 M $217 M
2024 Q3 86 50.9 M $58.6 M
2024 Q2 104 53.1 M $58.4 M
2024 Q1 107 55.5 M $69.1 M
2023 Q4 116 60.1 M $63.1 M
2023 Q3 165 70.6 M $483 M
2023 Q2 153 71.5 M $741 M
2023 Q1 177 71.7 M $580 M
2022 Q4 136 67.2 M $1.06 B
2022 Q3 133 64.1 M $1.01 B
2022 Q2 118 63.3 M $883 M
2022 Q1 114 59.3 M $1.02 B
2021 Q4 140 57.0 M $828 M
2021 Q3 132 56.8 M $1.02 B
2021 Q2 140 56.9 M $998 M
2021 Q1 110 46.1 M $1.31 B
2020 Q4 93 32.1 M $207 M
2020 Q3 61 25.6 M $65.7 M
2020 Q2 64 28.7 M $46.4 M
2020 Q1 74 32.1 M $33.4 M
2019 Q4 83 31.4 M $59.3 M
2019 Q3 84 29.1 M $31.4 M
2019 Q2 93 36.0 M $78.8 M
2019 Q1 101 37.9 M $227 M
2018 Q4 102 39.5 M $292 M
2018 Q3 91 30.6 M $444 M
2018 Q2 102 32.8 M $654 M
2018 Q1 102 30.7 M $537 M
2017 Q4 105 28.5 M $703 M
2017 Q3 108 28.5 M $737 M
2017 Q2 108 25.6 M $695 M
2017 Q1 115 23.7 M $708 M
2016 Q4 102 21.4 M $581 M
2016 Q3 59 15.5 M $397 M
2016 Q2 48 15.4 M $284 M
2016 Q1 34 14.6 M $277 M
2015 Q4 35 10.3 M $279 M